Farallon Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-21,400,000
| Closed | -$14.8M | – | 257 |
|
|
2020
Q4 | $14.8M | Sell |
21,400,000
-22,673,000
| -51% | -$15.6M | 0.09% | 97 |
|
|
2020
Q3 | $99.2M | Sell |
44,073,000
-127,000
| -0.3% | -$286K | 0.69% | 43 |
|
|
2020
Q2 | $158M | Buy |
44,200,000
+9,000,000
| +26% | +$32.2M | 1.27% | 31 |
|
|
2020
Q1 | $134M | Buy |
35,200,000
+4,825,050
| +16% | +$18.3M | 1.15% | 29 |
|
|
2019
Q4 | $91.4M | Buy |
+30,374,950
| New | +$91.4M | 0.62% | 36 |
|